NEW YORK, Jan. 14, 2016 /PRNewswire/ -- Report Details
Next-generation cancer diagnostics – our new study reveals trends, R&D progress, and predicted revenues
Where is the next-generation cancer diagnostics market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2025, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead
Our 176-page report provides 87 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in the growing next-generation cancer diagnostics market.
Forecasts from 2015-2025 and other analyses reveal the commercial prospects
- In addition to revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including SWOT analysis), product profiles and commercial developments.
- Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Keith Cannon, Executive Vice President, Aviva Biosciences
- Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you will find revenue forecasts to 2025 for the following submarkets:
- Advanced PCR Techniques
- In Situ Hybridisation
- Circulating Tumour Cells
- Next-Generation Sequencing
Our investigation discusses what stimulates and restrains business. You will understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.
Our analysis also divides the main global forecast into geographical markets.
What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for leading national markets from 2015-2025:
- EU5 (Germany, France, UK, Italy and Spain) as a group
- Rest of the World
There will be growth in established developed markets and in developing countries. Our analyses show that China, in particular, will continue to achieve high revenue growth to 2025. Greater uptake of existing technology and products worldwide will also stimulate the industry and market.
Leading companies and the potential for market growth
Overall world revenue for next-generation cancer diagnostics will reach $1.6bn in 2015, our work calculates. We predict strong revenue growth through to 2025. Market entry of NGS and CTCs together with increasing demand from emerging markets will increase sales to 2025.
Our work identifies which organisations that hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. See visiongain's analysis of the leading companies developing the most innovative cancer diagnostic technologies, including these:
- Roche Diagnostics
- Abbott Laboratories
- Thermo Fisher Scientific
- Agilent Technologies
- Myriad Genetics
What issues will affect the next-generation cancer diagnostics industry?
Our new report discusses the issues and events affecting the next-generation cancer diagnostics market. You will find discussions, including qualitative analyses:
Read the full report: http://www.reportlinker.com/p03247302-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001